Description / Application
Niraparib is a 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy. It has a role as a radiosensitizing agent, an antineoplastic agent, an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor and an apoptosis inducer.
Identities
| Alternative Name | (S)-2-(4-(Piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide |
|---|---|
| Molecular Formula | C19H20N4O |
| Molecular Weight | 320.4 |
| MFCD | MFCD17779309 |
Safety
| Pictograms |
|
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315;H319;H335 |
| Precautionary Statements | P261;P264;P271;P280;P302+P352;P304+P340;P305+P351+P338;P312;P321;P332+P313;P337+P313;P362;P403+P233;P405;P501 |